mAbs

Article	Citations
In silico prediction of post-translational modifications in therapeutic antibodies	292
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	217
Correction	120
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	95
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	86
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	85
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	72
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening	66
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries	61
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	60
Phenotypic whole-cell screening identifies a protective carbohydrate epitope on Klebsiella pneumoniae	59
An antibody developability triaging pipeline exploiting protein language models	57
Correction	55
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	46
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	44
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	41
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies	38
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	38
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	38
The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains	36
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	36
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	36
Correction	35
Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	34
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	34

GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	33
Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capability	30
Impact of IgG subclass on monoclonal antibody developability	30
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	30
Structural and functional characterization of a monoclonal antibody blocking TIGIT	28
Predicting antibody binders and generating synthetic antibodies using deep learning	27
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	27
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets	27
Antibodies to watch in 2024	26
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	25
Quantifying antibody binding: techniques and therapeutic implications	24
Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment	24
Sequence-based engineering of pH-sensitive antibodies for tumor targeting or endosomal recycling applications	24
T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice	23
Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG 1 antibody	22
Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody	22
Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19	22
Decoding the mannose receptor-mAb interaction: the importance of high-mannose N-glycans and glycan-pairing	21
Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan	21
Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production	21
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies	21
The eIg technology to generate Ig-like bispecific antibodies	20
Bivalent non-human gal-α1-3-gal glycan epitopes in the Fc region of a monoclonal antibody model can be recognized by anti-Gal-α1-3-Gal IgE antibodies	20
Rapid affinity-based purification of multi-specific antibodies using Kappa Select and Protein L	20
Cost and supply considerations for antibody therapeutics	19
Comprehensive characterization of higher order structure changes in methionine oxidized monoclonal antibodies via NMR chemometric analysis and biophysical approaches	19
In silico proof of principle of machine learning-based antibody design at unconstrained scale	19
Evolution of phage display libraries for therapeutic antibody discovery	18
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier	17
Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge	16
Electrostatic properties of human germlines and biodistribution of small biologics	16
A versatile design platform for glycoengineering therapeutic antibodies	16
Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality	15
Antigenic landscapes on Staphylococcus aureus pore-forming toxins reveal insights into specificity and cross-neutralization	15
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics	15
Deciphering deamidation and isomerization in therapeutic proteins: Effect of neighboring residue	15
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations	14
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG 1 antibodies	14
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties	14
IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation	14
Leveraging multi-modal feature learning for predictions of antibody viscosity	14
A glyco-engineering approach for site-specific conjugation to Fab glycans	14
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework	14
Efficient production of bispecific antibody by FAST-Ig TM and its application to NXT007 for the treatment of hemophilia A	13
Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains	13
Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features	13
Engineering death resistance in CHO cells for improved perfusion culture	13
Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach	12
Predicting purification process fit of monoclonal antibodies using machine learning	12
Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function	12

International nonproprietary names for monoclonal antibodies: an evolving nomenclature system	12
Reduction of monoclonal antibody viscosity using interpretable machine learning	12
Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows	12
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	12
Structural and biochemical differences between non-catalytic and catalytic antibodies	12
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays	12
With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process	11
Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation	11
Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1	11
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?	11
A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects	11
Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry	11
Coactivation of Tie2 and Wnt signaling using an antibody–R-spondin fusion potentiates therapeutic angiogenesis and vessel stabilization in hindlimb ischemia	11
A machine learning strategy for the identification of key in silico descriptors and prediction models for IgG monoclonal antibody developability properties	11
Understanding the structure–property relationship of bispecific monoclonal antibodies with Fc site-specific substitutions	10
Determination of ultra-trace metal-protein interactions in co-formulated monoclonal antibody drug product by SEC-ICP-MS	10
NAb-seq: an accurate, rapid, and cost-effective method for antibody long-read sequencing in hybridoma cell lines and single B cells	10
Correction	10
The impact of forced degradation conditions on mAb dimer formation and subsequent influence on aggregation propensity	10
Antibody markup language (AbML) — a notation language for antibody-based drug formats and software for creating and rendering AbML (abYdraw)	10
Upstream cell culture process characterization and in-process control strategy development at pandemic speed	10
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers	10
Development of QSAR models for in silico screening of antibody solubility	10
Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows	10
Illuminating a biologics development challenge: systematic characterization of CHO cell-derived hydrolases identified in monoclonal antibody formulations	9
An adapted consensus protein design strategy for identifying globally optimal biotherapeutics	9
Discovery and characterization of a monoclonal antibody targeting a conformational epitope of IL-6/IL-6Rα to inhibit IL-6/ IL-6Rα /gp130 hexameric signaling complex formation	9
Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy	9
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors	9
Identification and characterization of an unexpected isomerization motif in CDRH2 that affects antibody activity	9
Prediction of protein biophysical traits from limited data: a case study on nanobody thermostability through NanoMelt	8
IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine releas	8
Suitability of transiently expressed antibodies for clinical studies: product quality consistency at different production scales	8
A library approach for the de novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization	8
Targeted fusion of antibody-secreting cells: Unlocking monoclonal antibody production with hybridoma technology	8
Affinity-controlled capture and release of engineered monoclonal antibodies by macroporous dextran hydrogels using coiled-coil interactions	8
Computational models for studying physical instabilities in high concentration biotherapeutic formulations	8
Early determination of potential critical quality attributes of therapeutic antibodies in developability studies through surface plasmon resonance-based relative binding activity assessment	8
Epitope mapping of monoclonal antibodies: a comprehensive comparison of different technologies	8
High-throughput profiling of antibody self-association in multiple formulation conditions by PEG stabilized self-interaction nanoparticle spectroscopy	8
Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties	8
Modulation of the high concentration viscosity of IgG 1 antibodies using clinically validated Fc mutations	7
Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions	7
BERT2DAb: a pre-trained model for antibody representation based on amino acid sequences and 2D-structure	7
Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases	7
Accelerating high-concentration monoclonal antibody development with large-scale viscosity data and ensemble deep learning	7
Determining the affinities of high-affinity antibodies using KinExA and surface plasmon resonance	7
Correction	7
BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning	7
Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age	7
Development of T-cell engagers selective for cells co-expressing two antigens	7
Characterization of high-molecular weight by-products in the production of a trivalent bispecific 2+1 heterodimeric antibody	6
Analysis of how antigen mutations disrupt antibody binding interactions toward enabling rapid and reliable antibody repurposing	6
Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species	6
Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK/PD modeling for an anti-IL-11 antibody therapeutic	6
Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors	6
Fast-tracking antibody maturation using a B cell-based display system	6
Use of poxvirus display to select antibodies specific for complex membrane antigens	6
FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques	6
Proceedings of the 15 th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals	6
The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras	6
Molecular recognition requires dimerization of a VHH antibody	6
Large-scale data mining of four billion human antibody variable regions reveals convergence between therapeutic and natural antibodies that constrains search space for biologics drug discovery	6
Process development for production of non-originator NISTmAb from CHO and NS0 cell lines	6
Achieving Acceleration to First-in-Human: MSD’s Learnings on Platform Method Validation Strategy	6
Targeted chain-exchange-mediated reconstitution of a split type-I cytokine for conditional immunotherapy	6
A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity	6
Successful targeting of multidrug-resistant tumors with bispecific antibodies	6
Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors	6
Interplay of heavy chain introns influences efficient transcript splicing and affects product quality of recombinant biotherapeutic antibodies from CHO cells	6
Correction	5
Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition	5
Structure-based engineering of a novel CD3ε-targeting antibody for reduced polyreactivity	5
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy	5
Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice	5
A novel in vitro serum stability assay for antibody therapeutics incorporating internal standards	5
Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors	5
Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female-prevalent pain disorders	5
Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans	5
Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain	5

Recommended nomenclature convention for the NISTCHO cell line and its product monoclonal antibody, cNISTmAb	5
In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies	5
YAbS: The Antibody Society’s antibody therapeutics database	5
Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice	5
Strategies for clinical dose optimization of T cell-engaging therapies in oncology	5
Deciphering cross-species reactivity of LAMP-1 antibodies using deep mutational epitope mapping and AlphaFold	5
Design of orthogonal constant domain interfaces to aid proper heavy/light chain pairing of bispecific antibodies	4
Optimizing asymmetric antibody purification: a semi-automated process and its digital integration	4
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer	4
Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration	4
HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure	4
Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats	4
Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations	4
Mechanistic insights into the rational design of masked antibodies	4
Data-driven analyses of human antibody variable domain germlines: pairings, sequences and structural features	4
Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer	4
Expanding the structural resolution of glycosylation microheterogeneity in therapeutic proteins by salt-free hydrophilic interaction liquid chromatography tandem mass spectrometry	4
GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models	4
A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies	4
TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life	4
Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper	4
Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity	4
A perspective toward mass spectrometry-based de novo sequencing of endogenous antibodies	4
Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants	4
Correlated analytical and functional evaluation of higher order structure perturbations from oxidation of NISTmAb	4
Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering	4
Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET	4
How to think about designing smart antibodies in the age of genAI: integrating biology, technology, and experience	4